The estimated Net Worth of George Elston is at least $1.14 Millón dollars as of 25 May 2024. Mr. Elston owns over 7,500 units of EyePoint Pharmaceuticals Inc stock worth over $420,100 and over the last 15 years he sold EYPT stock worth over $0. In addition, he makes $716,008 as Chief Financial Officer and Head of Corporate Development at EyePoint Pharmaceuticals Inc.
George has made over 10 trades of the EyePoint Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of EYPT stock worth $61,650 on 25 May 2024.
The largest trade he's ever made was exercising 15,285 units of EyePoint Pharmaceuticals Inc stock on 5 January 2024 worth over $125,643. On average, George trades about 3,475 units every 109 days since 2009. As of 25 May 2024 he still owns at least 51,107 units of EyePoint Pharmaceuticals Inc stock.
You can see the complete history of Mr. Elston stock trades at the bottom of the page.
George Elston serves as Chief Financial Officer and Head of Corporate Development of the Company. Mr. Elston brings more than 25 years of diverse financial and senior leadership experience in the biopharmaceutical sector with both global publicly-traded and privately-held organizations. Most recently, Mr. Elston served as Chief Financial Officer and Head of Corporate Development at Enzyvant Therapeutics where he helped build the pre-commercial rare disease firm leading to its recent acquisition. He previously was President and Chief Executive Officer at 2X Oncology, Inc., where he advanced the Company from a spin-out into a multi-program, clinical-stage organization. He has also held senior executive roles at Juniper Pharmaceuticals, Inc., KBI Biopharma and Optherion, Inc. Mr. Elston began his career in public accounting at PriceWaterhouseCoopers. He earned his B.B.A. in accounting from Pace University and is a Certified Public Accountant. He currently serves as a Trustee and Audit Committee Chairman of the DWS – DBX ETF Trust.
As the Chief Financial Officer and Head of Corporate Development of EyePoint Pharmaceuticals Inc, the total compensation of George Elston at EyePoint Pharmaceuticals Inc is $716,008. There are 3 executives at EyePoint Pharmaceuticals Inc getting paid more, with Nancy Lurker having the highest compensation of $2,079,780.
George Elston is 55, he's been the Chief Financial Officer and Head of Corporate Development of EyePoint Pharmaceuticals Inc since 2019. There are 14 older and 3 younger executives at EyePoint Pharmaceuticals Inc. The oldest executive at EyePoint Pharmaceuticals Inc is Goran Ando, 71, who is the Independent Chairman of the Board.
George's mailing address filed with the SEC is C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN, MA, 02472.
Over the last 6 years, insiders at EyePoint Pharmaceuticals Inc have traded over $67,100,515 worth of EyePoint Pharmaceuticals Inc stock and bought 21,910,863 units worth $111,404,456 . The most active insiders traders include Healthcare Partners, L.P.Ew..., Asset Management, Lp Chen B... y Ye Liu. On average, EyePoint Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $1,746,068. The most recent stock trade was executed by Goran Ando on 21 August 2024, trading 5,000 units of EYPT stock currently worth $39,750.
psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®
EyePoint Pharmaceuticals Inc executives and other stock owners filed with the SEC include: